These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24960148)

  • 1. Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.
    Baker DL; Peng K; Cheu M; Fischer SK
    Curr Med Res Opin; 2014 Oct; 30(10):1927-9. PubMed ID: 24960148
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin 2014;30:913-22.
    Strohner P; Becher G
    Curr Med Res Opin; 2014 Oct; 30(10):1923-5. PubMed ID: 24914579
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.
    Baker DL; Peng K; Cheu M; Fischer SK
    Curr Med Res Opin; 2014 May; 30(5):913-22. PubMed ID: 24354863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
    Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
    Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.
    Lowe PJ; Georgiou P; Canvin J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):68-77. PubMed ID: 25497995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
    Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
    Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
    Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
    Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
    Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Allergic Patients on Omalizumab with Free and Total Serum IgE Measurements.
    Hamilton RG
    J Allergy Clin Immunol Pract; 2016; 4(2):366-8. PubMed ID: 26968963
    [No Abstract]   [Full Text] [Related]  

  • 14. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
    van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
    Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R; Marco AG; Cohen D; Canonica GW
    Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inaccuracies in total serum IgE measurements by immulite caused by omalizumab in specimens.
    Hamilton RG
    J Asthma; 2012 Apr; 49(3):324-5. PubMed ID: 22316119
    [No Abstract]   [Full Text] [Related]  

  • 17. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
    Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg.
    Lafuente I; Mazon A; Nieto M; Uixera S; Pina R; Nieto A
    Pediatr Allergy Immunol; 2014 Nov; 25(7):717-9. PubMed ID: 24902874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.